Table 2.

Cytokine and chemokine expression in mixed glial primary cultures.

	TNF-alpha	IFN-alpha	CXCL9	CXCL10
Control + NO donor	0.71 ± 0.03	0.45 ± 0.01	0.94 ± 0.02	1.27 ± 0.34
Control + iNOS inhibitor	1.01 ± 0.02	1.1 ± 0.45	0.17 ± 0.04	1.1 ± 0.03
sFasL	8.88 ± 1.89†	4.5 ± 0.7†	45.2 ± 0.54††	n.d.
HSV-1	86 ± 9.1††	7422 ± 892††	152 ± 29††	424 ± 39††
HSV − 1 + NO donor	189±35∗∗	1247±299∗∗	95 ± 23∗	146±49∗∗
HSV − 1 + iNOS inhibitor	79 ± 12	10401±501∗∗	294±51∗∗	215±61∗∗
HSV − 1 + sFasL	43 ± 5∗	5673 ± 1329	445±91∗∗	552 ± 59∗∗
HSV − 1 + NO donor + sFasL	49 ± 6.6∗	6427 ± 987	110 ± 23∗	150±45∗∗

Cytokine and chemokine expression changes in the mixed glial cultures at 24 h p.i. with HSV-1. Mixed glial cultures were subjected to treatment with the NO donor—SNP (100 μM)—or the inhibitor of iNOS—AMG (50 μM). mRNA levels of IFN-alpha, TNF-alpha, CXCL9, and CXCL10 are shown as expression relative to control on the basis of the 2^−∆∆Ct method. mRNA levels were counted from three PCR reactions for each sample. ^∗p ≤ 0.05 and ^∗∗p ≤ 0.01 versus HSV-1-infected control and ^†p ≤ 0.05 and ^††p ≤ 0.01 versus uninfected control. n.d. means not detected.